Wave Life Sciences shares are down significantly this year, trading near their 52-week low with a market cap around $1 billion. The company, focused on RNA-based medicines, holds substantial cash but is currently unprofitable. Its key assets include promising RNA therapies for obesity, liver disease, and genetic disorders, attracting interest from major pharma companies like GSK, Eli Lilly, Novo Nordisk, and Amgen. Upcoming FDA meetings and clinical trial results could act as catalysts for the stock, while acquisition or alternative financing remain possible paths forward.
President Trump's executive order to separate the combined MMR vaccine into individual shots faces significant regulatory and manufacturing challenges, with FDA approval potentially taking up to 10 years. Merck and GSK, the only licensed producers of...
President Donald Trump signed an executive order to separate the combined MMR vaccine into three individual shots, citing unproven claims linking the combined vaccine to autism. Medical experts strongly reject this, emphasizing the vaccine's safety a...
Theravance Biopharma announced a definitive agreement for acquisition by Zymeworks, expected to close in the second half of 2026 pending shareholder approval. The company's Q2 2026 revenue rose 11% year-over-year to $20.7 million, driven by growth in...
